NCT07096128View on ClinicalTrials.gov

A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

April 30, 2027

Conditions
mCRPC
Interventions
DRUG

[177Lu]Lu-PSMA-XT

\[177Lu\]Lu-PSMA-XT is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells.

Trial Locations (3)

100000

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Mianyang Central Hospital, Beijing

RECRUITING

The First Medical Center, Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

Sinotau Pharmaceutical Group

INDUSTRY

lead

Jinming Zhang

OTHER